ReviewThe Journal of experimental medicine2015
Transformative tools for tackling tuberculosis.
Review in The Journal of experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Outlook for CRISPR-based tuberculosis assays now in their infancy.Frontiers in immunology · 2023Pooled it
- A Dual, Systematic Approach to Malaria Diagnostic Biomarker Discovery.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Pooled it
- Upper respiratory tract commensalJournal of thoracic disease · 2026Article
- Antibodies as clinical tools for tuberculosis.Frontiers in immunology · 2023Review
- Mass Spectrometry-Based Proteomic and Metabolomic Profiling of Serum Samples for Discovery and Validation of Tuberculosis Diagnostic Biomarker Signature.International journal of molecular sciences · 2022Article
- Discovery of serum biomarkers for diagnosis of tuberculosis by NMR metabolomics including cross-validation with a second cohort.Biomedical journal · 2022Article
- CRISPR detection of circulating cell-free Mycobacterium tuberculosis DNA in adults and children, including children with HIV: a molecular diagnostics study.The Lancet. Microbe · 2022Article
- Feasibility of novel approaches to detect viableFrontiers in medicine · 2022Review
- Advances in activity-based diagnostics for infectious disease and microbiome health.Current opinion in biomedical engineering · 2021Article
- Differential Expression of Activation Markers by Mycobacterium tuberculosis-specific CD4+ T Cell Distinguishes Extrapulmonary From Pulmonary Tuberculosis and Latent Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Challenges and controversies in the treatment of spinal tuberculosis.Journal of clinical tuberculosis and other mycobacterial diseases · 2020Review
- Host Blood RNA Transcript and Protein Signatures for Sputum-Independent Diagnostics of Tuberculosis in Adults.Frontiers in immunology · 2020Article
- Disease extent and anti-tubercular treatment response correlates withClinical & translational immunology · 2020Article
- Toward the Development of a Circulating Free DNA-BasedJournal of clinical microbiology · 2019Review
- An Auto-luminescent Fluorescent BCG Whole Blood Assay to Enable Evaluation of Paediatric Mycobacterial Responses Using Minimal Blood Volumes.Frontiers in pediatrics · 2019Article
- Article
- Evaluation of Tuberculosis Treatment Response With Serial C-Reactive Protein Measurements.Open forum infectious diseases · 2018Article
- Mycobacteria-derived biomarkers for tuberculosis diagnosis.The Indian journal of medical research · 2017Review
- Discovery and Validation of a Six-Marker Serum Protein Signature for the Diagnosis of Active Pulmonary Tuberculosis.Journal of clinical microbiology · 2017Article
- Potential of High-Affinity, Slow Off-Rate Modified Aptamer Reagents for Mycobacterium tuberculosis Proteins as Tools for Infection Models and Diagnostic Applications.Journal of clinical microbiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The world is in need of more effective approaches to controlling tuberculosis. The development of improved control strategies has been hampered by deficiencies in the tools available for detecting Mycobacterium tuberculosis and defining the dynamic consequences of the interaction of M. tuberculosis with its human host. Key needs include a highly sensitive, specific nonsputum diagnostic; biomarkers predictive of responses to therapy; correlates of risk for disease development; and host response-independent markers of M. tuberculosis infection. Tools able to sensitively detect and quantify total body M. tuberculosis burden might well be transformative across many needed use cases. Here, we review the current state of the field, paying particular attention to needed changes in experimental paradigms that would facilitate the discovery, validation, and development of such tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.